TacticScaleWhat Edwards Lifesciences Does & How It Makes Money (EW)
Updated October 2026 · reflects Edwards Lifesciences's latest reported financials
Medical device maker specializing in heart valve replacement and repair. It earns revenue by selling heart valve devices and related systems to hospitals and physicians, both through its own direct sales force and through independent distributors in the US, Europe, Japan and other markets.
How Edwards Lifesciences makes money
It earns revenue by selling heart valve devices and related systems to hospitals and physicians, both through its own direct sales force and through independent distributors in the US, Europe, Japan and other markets.
What Edwards Lifesciences does
Edwards Lifesciences is a medical device company focused on structural heart disease, meaning problems with the heart's valves. Its main business is transcatheter heart valves. The Edwards SAPIEN family is used to replace diseased aortic valves in a minimally invasive procedure. The company has also moved into the mitral and tricuspid valves: PASCAL is used for valve repair and EVOQUE for replacement. The company also has a surgical structural heart business built around its RESILIA tissue technology. Products include the INSPIRIS RESILIA aortic valve, the KONECT RESILIA valve conduit for complex combined procedures, and the MITRIS RESILIA mitral valve. Edwards was founded in 1958 and is headquartered in Irvine, California. It sells in the US, Europe, Japan and other international markets through its own direct sales force and independent distributors.
Products & services
- Edwards SAPIEN transcatheter aortic valves
- PASCAL transcatheter valve repair system
- EVOQUE tricuspid valve replacement
- INSPIRIS RESILIA aortic surgical valve
- KONECT RESILIA valve conduit
- MITRIS RESILIA mitral valve
What is Edwards Lifesciences worth?
On an owner-earnings DCF, Edwards Lifesciences's most-likely value is about $83 versus a recent price near $85 (2% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$29) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Boston Scientific (BSX) · Medtronic (MDT) · Artivion (AORT) · LeMaitre Vascular (LMAT) · LivaNova (LIVN)